Pharmaceuticals, Biotechnology and Life Sciences
UBM EMEA’s Pharmapack Europe 2017 has named the winners of the 2017 Pharmapack Awards on Wednesday, picking four innovations in the Exhibitor Innovation category, while two winners were chosen to get awards in the Health Product category.
NeuroVive Pharmaceutical, the mitochondrial medicine company, will present preclinical data from a new generation of sanglifehrin-based compounds with potent inhibitory…
Danish provider of clinical diagnostic tests BioPorto, has finalized a distribution deal with Simens Healthcare for delivery of a NGAL test adapted for Siemens Healthcare BN II and BN ProSpec Systems.
Galapagos has started dosing of the first patient with cystic fibrosis (CF) Class III (F508del and a gating mutation like G551D)…
Pharnext, a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, has announced publication in PLoS One of statistical findings evaluating the clinical scale Charcot-Marie-Tooth Neuropathy Score (CMTNS) for application in Charcot-Marie-Tooth Disease Type 1A (CMT1A).
AstraZeneca’s hopes to launch several cancer, respiratory and metabolic diseases drugs, as it expects to see the effects of its long-term growth. The drugmaker nears the end of its patent-expiry period as it expects to bring new medicines to the stores is.
Novo Nordisk has reported net profit increased by 9% to Eur 5,1 billion. Diluted earnings per share increased by 11% to Eur 2,01.
Diplomat Pharmacy has concluded the purchase of a Houston based pharmacy and infusion services specialist Affinity Biotech, which focuses on treating patients with hemophilia.
Pfizer has reported 11% growth for full-year 2016 revenues, reaching $52.8 billion, including the business from Hospira and the legacy of Medivation. Net income for full year was $7,215 million which is up 4% from last years total net income of $6,960.
Allergan has completed the $2.9 billion purchase of Acelity’s subsidiary LifeCell, adding commercial products to its regenerative medicine portfolio, and LifeCell’s innovative manufacturing capabilities and its R&D operations, based in New Jersey.